# BioXcel Therapeutics, Inc. (BTAI) — capital_raise [announced]
Source: SEC API (secapi.ai) · situation sit_0e15bb7c72bafceb601a · retrieved 2026-08-11T15:52:45.009Z

## Overview
BioXcel Therapeutics, Inc. is a pharmaceutical company that develops and commercializes innovative therapeutics; it is incorporated in Delaware and trades on the Nasdaq Capital Market under ticker BTAI.

BioXcel Therapeutics entered into the Eleventh Amendment to its Credit Agreement on July 31, 2026, with lenders including Oaktree-affiliated funds and Q Boost Holding LLC. The amendment defers a principal and interest payment of $9,016,914.47 from July 31, 2026 to August 31, 2026, plus all accrued interest and fees through that date. The minimum liquidity covenant was reduced from $7.5 million to $6.25 million. Critically, the company must enter into definitive agreements by August 10, 2026 for either (A) a transaction that repays all loan obligations in full, or (B) an alternative capital solutions transaction acceptable to the lenders, or face potential default.

## Terms
- Counterparty: Oaktree Fund Administration LLC (administrative agent) and Oaktree-affiliated lenders; Q Boost Holding LLC · Deal value: $9.0M · Consideration: cash

## Key dates
- Announced 2026-08-03 · Expiry 2026-08-10

## Timeline
- 2026-08-03 · 8-K (0001104659-26-089436): 8-K - BioXcel Therapeutics, Inc. — *BioXcel Therapeutics, Inc. is a pharmaceutical company that develops and commercializes innovative therapeutics; it is incorporated in Delaware and trades on the Nasdaq Capital Market under ticker BTAI.* BioXcel Therapeutics entered into the Eleventh Amendment to its Credit Agreement on July 31, 2026, with lenders including Oaktree-affiliated funds and Q Boost Holding LLC. The amendment defers a principal and interest payment of $9,016,914.47 from July 31, 2026 to August 31, 2026, plus all accrued interest and fees through that date. The minimum liquidity covenant was reduced from $7.5 million to $6.25 million. Critically, the company must enter into definitive agreements by August 10, 2026 for either (A) a transaction that repays all loan obligations in full, or (B) an alternative capital solutions transaction acceptable to the lenders, or face potential default.
  https://www.sec.gov/Archives/edgar/data/1720893/0001104659-26-089436.txt

## Citations
- 0001104659-26-089436 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926089436